Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model

Liver International

Volumn 36, Issue 12, 2016, Pages 1765-1773

  Petta, Salvatore ^a   Di Marco, Vito ^a   Bruno, Savino ^b   Enea, Marco ^c   Calvaruso, Vincenza ^a   Boccaccio, Vincenzo ^b   Rossi, Sonia ^b   Craxì, Antonio ^a   Cammà, Calogero ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c CNR   (Italy)

Author keywords

cirrhosis; HCV; multistate; SVR

Indexed keywords

PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; ESOPHAGUS VARICES; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INFECTION RISK; LIVER CELL CARCINOMA; LIVER HISTOLOGY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PROSPECTIVE STUDY; VIRAL CLEARANCE; AGED; ESOPHAGEAL AND GASTRIC VARICES; HEPACIVIRUS; HEPATITIS C, CHRONIC; ITALY; LIVER; LIVER CIRRHOSIS; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; SUSTAINED VIROLOGIC RESPONSE; VIROLOGY;

AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; ITALY; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SUSTAINED VIROLOGIC RESPONSE;

EID: 84995488363     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13156     Document Type: Article

References (35)

1. Reddy KR, Bourlière M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 2015; 62: 79–86.
2. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973–82.
3. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649–59.
4. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579–87.
5. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677–84.
6. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833–44.
7. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584–93.
8. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, child-pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51: 2069–76.
9. Di Marco V, Calvaruso V, Grimaudo S, et al. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. J Viral Hepat 2013; 20: 113–21.
10. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421–30.
11. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–2.
12. de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000; 33: 846–52.
13. North-Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1988; 319: 983–9.
14. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43: 167–76.
15. de Franchis R, Faculty BV. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53: 762–8.
16. Martin P, Di Martini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59: 1144–65.
17. Therneau TM, Grambsch PM. Modeling Survival Data. Extending the Cox Model. Statistics for Biology and Health. New York: Springer, 2000.
18. Kay R. The analysis of transition times in a multistate stochastic process using proportional hazard regression models. Commun Stat Theory Methods 1983; 11: 1743–56.
19. Andersen PK, Keiding N. Multi-state models for event history analysis. Stat Methods Med Res 2002; 11: 91–115.
20. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007; 26: 2389–430.
21. Klein JP, Keiding N, Copelan EA. Plotting summary predictions in multistate survival models – probabilities of relapse and death in remission for bone-marrow transplantation patients. Stat Med 1994; 12: 2315–32.
22. R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing, 2015. http://www.R-project.org/.
23. Therneau T. A Package for Survival Analysis in S. R package version 2.37-7, 2014. http://CRAN.R-project.org/package=survival.
24. de Wreede LC, Fiocco M, Putter H. mstate: an R package for the analysis of competing risks and multi-state models. J Stat Softw 2011; 38: 1–30. http://www.jstatsoft.org/v38/i07/.
25. Sakamoto Y, Ishiguro M, Kitagawa G. Akaike Information Criterion Statistics D. Reidel Publishing Company, 1986.
26. D'Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 2014; 39: 1180–93.
27. Trinchet JC, Bourcier V, Chaffaut C, et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology 2015; 62: 737–50.
28. Arase Y, Kobayashi M, Suzuki F, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013; 57: 964–73.
29. Petta S, Macaluso FS, Craxì A. Cardiovascular diseases and HCV infection: a simple association or more? Gut 2014; 63: 369–75.
30. Negro F, Forton D, Craxì A, et al. Extra-hepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 2015; 149: 1345–60.
31. Petta S, Maida M, Macaluso FS, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology 2016; 150: 145–155. e4.
32. Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut 2015; 64: 495–503.
33. Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59: 1293–302.
34. Innes HA, McDonald SA, Dillon JF, et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology 2015; 62: 355–64.
35. Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970–9, 1979.e1–3.